01:46 , Aug 17, 2018 |  BC Innovations  |  Targets & Mechanisms

Unsaturated remyelination

Enzymes downstream in cholesterol biosynthesis could provide new ways to stimulate remyelination that avoid the baggage of previously identified multiple sclerosis targets, according to a group at Case Western. The university is spinning out Convelo...
15:41 , Jul 18, 2018 |  BC Innovations  |  Distillery Techniques

Drug platforms

TECHNOLOGY: Peptides A fibrin matrix loaded with synthetic laminin peptides that bind growth factors could be used for wound healing and tissue regeneration applications. The peptides are 24- and 19-mer synthetic analogs of human laminin α...
02:17 , Jun 9, 2018 |  BioCentury  |  Finance

ASCO ascent

Kinase inhibitor company Deciphera Pharmaceuticals Inc. (NASDAQ:DCPH) and cancer assay developer Genomic Health Inc. (NASDAQ:GHDX) each hit all-time highs in the wake of data readouts at the American Society of Clinical Oncology meeting in Chicago. Deciphera...
16:47 , Jun 8, 2018 |  BC Week In Review  |  Company News

Cstone gets Chinese rights to Blueprint clinical pipeline

Blueprint Medicines Corp. (NASDAQ:BPMC) granted CStone Pharmaceuticals Co. Ltd. (Suzhou, China) exclusive rights to all three of Blueprint's clinical candidates in a deal potentially worth more than $386 million. CStone gained exclusive rights to develop and...
15:27 , Jun 8, 2018 |  BC Week In Review  |  Clinical News

Pfizer's Sutent improves survival without surgery in RCC patients

Data from the Phase III CARMENA trial evaluating Sutent sunitinib from Pfizer Inc. (NYSE:PFE) showed that patients with renal cell carcinoma (RCC) could avoid nephrectomy without compromising survival. The data were presented at the American...
15:24 , Jun 8, 2018 |  BC Week In Review  |  Clinical News

Deciphera reports updated Phase I data for DCC-2618 in GIST

Deciphera Pharmaceuticals Inc. (NASDAQ:DCPH) reported updated data at the American Society of Clinical Oncology (ASCO) meeting in Chicago from heavily pretreated patients with gastrointestinal stromal tumors (GIST) who received the company's DCC-2618 in a Phase...
15:07 , Jun 8, 2018 |  BC Week In Review  |  Financial News

Madrigal, Deciphera raise money after readouts

Madrigal Pharmaceuticals Inc. (NASDAQ:MDGL) and Deciphera Pharmaceuticals Inc. (NASDAQ:DCPH) each priced upsized offerings. Each company's stock had risen sharply after auspicious data readouts. Madrigal raised $300 million through the sale of 983,607 shares at $305 in...
13:13 , Jun 7, 2018 |  BC Extra  |  Financial News

Madrigal, Deciphera raise money after readouts

Madrigal Pharmaceuticals Inc. (NASDAQ:MDGL) and Deciphera Pharmaceuticals Inc. (NASDAQ:DCPH) each priced upsized offerings late Wednesday. Each company's stock has risen sharply in recent days after auspicious data readouts. Madrigal raised $300 million through the sale of...
22:12 , Jun 4, 2018 |  BC Extra  |  Company News

CStone gains China rights to Blueprint programs

Blueprint Medicines Corp. (NASDAQ:BPMC) granted CStone Pharmaceuticals Co. Ltd. (Suzhou, China) exclusive rights to all three of Blueprint's clinical candidates in a deal potentially worth more than $386 million. CStone gained exclusive rights to develop...
20:12 , Jun 4, 2018 |  BC Extra  |  Clinical News

Deciphera rises on GIST response data, proposes follow-on

Deciphera Pharmaceuticals Inc. (NASDAQ:DCPH) added $12.40 (48%) to $38.31 on Monday after reporting updated data from heavily pretreated patients with gastrointestinal stromal tumors who received the company's DCC-2618 in a Phase I trial. The data...